You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

KYTRIL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Kytril patents expire, and when can generic versions of Kytril launch?

Kytril is a drug marketed by Roche and is included in three NDAs.

The generic ingredient in KYTRIL is granisetron hydrochloride. There are twenty-six drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the granisetron hydrochloride profile page.

Drug patent expirations by year for KYTRIL
Recent Clinical Trials for KYTRIL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Rutgers UniversityN/A
National Institute of General Medical Sciences (NIGMS)N/A
University of Colorado, DenverN/A

See all KYTRIL clinical trials

Paragraph IV (Patent) Challenges for KYTRIL
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
KYTRIL Injection granisetron hydrochloride 0.1 mg/mL, 1 mL single dose vial 020239 1 2007-03-08
KYTRIL Injection granisetron hydrochloride 1 mg/mL, 4 mL multi-dose vials 020239 1 2004-07-19
KYTRIL Injection granisetron hydrochloride 1 mg/mL, 1 mL vials 020239 1 2004-06-01

US Patents and Regulatory Information for KYTRIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Roche KYTRIL granisetron hydrochloride INJECTABLE;INJECTION 020239-003 Sep 17, 2004 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Roche KYTRIL granisetron hydrochloride TABLET;ORAL 020305-002 Jun 15, 1998 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Roche KYTRIL granisetron hydrochloride INJECTABLE;INJECTION 020239-002 Mar 11, 1994 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for KYTRIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Roche KYTRIL granisetron hydrochloride TABLET;ORAL 020305-001 Mar 16, 1995 ⤷  Try a Trial ⤷  Try a Trial
Roche KYTRIL granisetron hydrochloride INJECTABLE;INJECTION 020239-003 Sep 17, 2004 ⤷  Try a Trial ⤷  Try a Trial
Roche KYTRIL granisetron hydrochloride INJECTABLE;INJECTION 020239-002 Mar 11, 1994 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for KYTRIL

See the table below for patents covering KYTRIL around the world.

Country Patent Number Title Estimated Expiration
Denmark 191186 ⤷  Try a Trial
Hong Kong 66993 AZABICYCLONONYL-INDAZOLE-CARBOXAMIDE HAVING 5-HT ANTAGONIST ACTIVITY ⤷  Try a Trial
European Patent Office 0223385 8-AZABICYCLO(3,2,1)OCTANE AND 9-AZABICYCLO(3,3,1)NONANE DERIVATIVES ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.